SOURCE: Peregrine Pharmaceuticals

Peregrine Pharmaceuticals

November 05, 2013 16:00 ET

Peregrine Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference

TUSTIN, CA--(Marketwired - Nov 5, 2013) -  Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that Steven W. King, president and chief executive officer, will present a company update at the Credit Suisse 2013 Healthcare Conference on Tuesday, November 12, 2013 at 1:00 PM Mountain Time (3:00 PM Eastern Time) at The Phoenician Hotel, Scottsdale, Arizona.

Peregrine's presentation will be webcast live and available for replay for 30 days at:

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at

Contact Information

  • Contact:
    Christopher Keenan or Jay Carlson
    Peregrine Pharmaceuticals
    (800) 987-8256